NCI-006

Description

NCI-006 is an orally active lactate dehydrogenase LDH inhibitor LDHA IC50 = 0.06 ?M; LDHB IC50 = 0.03 ?M . NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells 1522, skin fibroblasts in combination with ionizing radiation IR . NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 HY-112037 against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model.